Project Grant R01CA291607

Award Date 6/1/24
Completion Date 5/31/29
Dollars Obligated $578K
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a Project Grant totaling $2,042,210 to the University of Alabama at Birmingham (UAB) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant, running from September 2024 to June 2029, will support comprehensive research to understand the mechanisms by which chronic HIV infection and associated inflammation increase the risk of oropharyngeal cancer (OPC) development in persons living with HIV (PWH)....
This Project Grant award, titled "TARGETING THE DNA DAMAGE RESPONSE IN HPV+ HEAD AND NECK CANCER", was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The award, valued at $249,000.00 and running from June 2024 to May 2027, supports research aimed at understanding how human papillomavirus (HPV) disrupts DNA damage response signaling in head and neck squamous cell carcinoma (HNSCC)....
This federal Project Grant award, valued at $637,738 and issued by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), will fund research to investigate the role of antiretroviral therapy (ART) in susceptibility to oral human papillomavirus (HPV) infection. The award will support three specific aims: 1) comparing the prevalence and incidence of oral HPV infection in people living with HIV taking ART, people...
This $634,061 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment of liver cancer, or hepatocellular carcinoma (HCC), during HIV infection. The key objectives are to: 1) Characterize how TAPDC reprogram the HCC tumor immune microenvironment, and how HIV infection affects TAPDC and the tumor immune microenvironment; 2) Define how TAPDC...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), part of the Oral Diseases and Disorders Research program (CFDA 93.121), provides $2,942,347 to the Regents of the University of Michigan to conduct research on human papillomavirus (HPV) integration in head and neck squamous cell carcinoma (HNSCC). The key objectives are to determine the accuracy of using short-read sequencing technologies to identify the structural mechanisms of HPV...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $515,812 Project Grant under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121) to The Johns Hopkins University. The grant, with a period of performance from September 15, 2024 to September 14, 2025, will support research to study the progression of HPV-related oropharynx cancer (HPV-OPC) in people living with and without HIV. The key objectives are to: 1) study the progression to HPV-OPC and...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $164,322 to investigate how myeloid cell evolution impacts the progression from oral epithelial dysplasia to head and neck squamous cell carcinoma. The research aims to develop a high-resolution atlas of functionally distinct myeloid cell subsets in precancerous lesions and identify key intervention points for therapeutic...
This $4,947,572 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund a cohort study to evaluate the effectiveness of the HPV vaccine in preventing anogenital disease among immunocompromised populations. The study will assess vaccine effectiveness across three distinct groups: people living with HIV, people with autoimmune conditions, and people with a history of solid...
The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), awarded a $2,796,216 Project Grant to Case Western Reserve University (CWRU) for the project "DUAL P300 AND P53 REACTIVATION IN HPV+ HEAD AND NECK CANCER". The project aims to extensively determine the mechanisms of action of p53 and p300 reactivation in response to the lead molecule OHM1, which disrupts the HPV E6-p300 interaction...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $164,000 to evaluate the feasibility and acceptability of using mail-delivered sample collection kits to detect oral human papillomavirus (HPV) infection among racially and ethnically diverse men living with HIV. The pilot study will assess the agreement between at-home self-collected samples and clinic-collected...

DISSECTING TUMOR-IMMUNE INTERACTIONS IN HIV-HPV CO-INFECTION-ASSOCIATED OROPHARYNGEAL CANCER USING SINGLE CELL SEQUENCING AND NOVEL MOUSE MODELS - PROJECT SUMMARY/ABSTRACT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC) HAS EMERGED AS A SIGNIFICANT GLOBAL HEALTH CONCERN, WITH INCREASING INCIDENCE ATTRIBUTED TO HUMAN PAPILLOMAVIRUS (HPV) INFECTION. ADDITIONALLY, INDIVIDUALS LIVING WITH HIV/AIDS (PLWH) FACE A HIGHER RISK OF DEVELOPING OPSCC. UNDERSTANDING THE SYNERGISTIC RELATIONSHIPS BETWEEN HIV AND ORAL HPV INFECTION IN OPSCC DEVELOPMENT IS CRITICAL FOR ADVANCING PREVENTION, DIAGNOSIS, AND TREATMENT STRATEGIES. CD8+ T CELLS PLAY A PIVOTAL ROLE IN ANTIVIRAL IMMUNITY AND TUMOR SURVEILLANCE. HOWEVER, THE IMPACT OF HIV INFECTION ON CD8+ T CELLS REMAINS LARGELY UNEXPLORED. RECENTLY, WE HAVE IDENTIFIED AN HPV INTEGRATION HOTSPOT IN THE PD-L1 GENE, CONTRIBUTING TO CD8+ T CELL EXHAUSTION. IN ADDITION, OUR SINGLE-CELL ANALYSIS REVEALED A UNIQUE SUBSET OF EXHAUSTED CD8+ T CELLS ASSOCIATED WITH HIV-HPV CO-INFECTION IN THE OPSCC MICROENVIRONMENT. WE HYPOTHESIZE THAT HIV CO-INFECTION INDUCES ELEVATED DYSFUNCTION/EXHAUSTION OF TUMOR- INFILTRATING LYMPHOCYTES (TILS), PARTICULARLY CD8+ T CELLS, IN THE OPSCC MICROENVIRONMENT. AS A MULTI-PI APPLICATION, COMBINING OUR EXPERTISE IN SINGLE-CELL ANALYSIS AND FUNCTIONAL ANALYSIS OF HIV MOUSE MODELS AND CD8+ T CELLS, WE WILL INVESTIGATE THE IMPACT OF HIV INFECTION ON THE IMMUNE CELL LANDSCAPE OF HPV-POSITIVE OPSCC (AIM 1). ADDITIONALLY, WE WILL CHARACTERIZE THE PHENOTYPE AND SPECIFICITY OF TUMOR-INFILTRATING CD8+ T CELL RECEPTORS (TCRS) AND CORRELATE THEM WITH CELLULAR EXHAUSTION STATUS IN THE CONTEXT HIV-HPV CO-INFECTION (AIM 2). FURTHERMORE, WE WILL ESTABLISH A NOVEL MOUSE MODEL THAT FAITHFULLY RECAPITULATES HIV-HPV CO-INFECTION IN OPSCC TO EXPLORE DYNAMIC INTERACTIONS BETWEEN VIRAL INFECTION, TUMOR PROGRESSION, AND CD8+ T CELLS (AIM 3). ADDITIONALLY, WE WILL INVESTIGATE THE IMPACT OF COMBINED ANTIRETROVIRAL THERAPY (ART) AND IMMUNE CHECKPOINT BLOCKADE ON RESTORING TUMOR-REACTIVE CD8+ T CELL FUNCTION AND PREVENTING HPV-INDUCED NEOPLASTIC GROWTH. THIS RESEARCH AIMS TO ENHANCE OUR UNDERSTANDING OF HIV-HPV CO-INFECTION'S INFLUENCE ON IMMUNE RESPONSES AND IMMUNE EVASION IN OROPHARYNGEAL CANCER. FINDINGS MAY INFORM NOVEL THERAPEUTIC STRATEGIES TO ENHANCE IMMUNE RESPONSES AND IMPROVE CLINICAL OUTCOMES FOR OPSCC PATIENTS LIVING WITH HIV AND HAVE BROADER IMPLICATIONS FOR OTHER HPV-ASSOCIATED MALIGNANCIES.

Posted 5/22/24, 12:00 AM